Rigel Pharmaceuticals, Inc.
Price Action
Technical Summary
EMERGING TRENDRigel Pharmaceuticals, Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is moderate (RS Rating: 76), indicating performance broadly in line with the market. Earnings contraction of 30% provides fundamental context to the price action. However, with RSI at 79, the stock is extended and may be prone to a short-term pullback.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $33.09 | +17.99% | ABOVE |
| 50 SMA | $30.95 | +26.14% | ABOVE |
| 100 SMA | $30.71 | +27.10% | ABOVE |
| 150 SMA | $34.49 | +13.18% | ABOVE |
| 200 SMA | $34.00 | +14.81% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is RIGL in an uptrend right now?
RIGL has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is RIGL overbought or oversold?
RIGL's RSI (14) is 79. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is RIGL outperforming the market?
RIGL has a Relative Strength (RS) Rating of 76 out of 99. RIGL is performing about average compared to the market.
Where is RIGL in its 52-week range?
RIGL is trading at $39.04, which is 75% of its 52-week high ($52.24) and 61% above its 52-week low ($18.24).
How volatile is RIGL?
RIGL has a Beta of 0.91 and 52-week volatility of 70%. It's less volatile than the S&P 500 - generally more stable.